Severe and long-lasting alteration of albumin redox state by plasmapheresis

Boss, Kristina; Stettner, Mark; Szepanowski, Fabian; Mausberg, Anne K.; Paar, Margret; Pul, Refik; Kleinschnitz, Christoph; Oettl, Karl; Kribben, Andreas

doi:10.1038/s41598-022-16452-4

Cited by 3 publications

(5 citation statements)

References 29 publications

(36 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in contrast to the modest changes observed after albumin infusion, a recent study in patients with neurological disorders reported long-lasting increases in HNA2 levels by plasma exchange but not by immunoadsorption, presumably related to the high volume of albumin substitution in plasma exchange. 23 High content of oxidized albumin in therapeutic albumin solutions has been previously reported by Bar-Or et al 15 In their study, analysis by mass spectrometry revealed oxidative albumin modification at Cys-34 in 57% of commercial albumin versus 23% of plasma albumin of healthy volunteers. This finding was confirmed by our group using HPLC.…”

Section: Discussionmentioning

confidence: 52%

“…On the other hand, early decline of plasma levels of both native and oxidized albumin may be related to rapid loss into the extravascular pool. Interestingly, in contrast to the modest changes observed after albumin infusion, a recent study in patients with neurological disorders reported long‐lasting increases in HNA2 levels by plasma exchange but not by immunoadsorption, presumably related to the high volume of albumin substitution in plasma exchange 23 …”

Section: Discussionmentioning

confidence: 87%

See 1 more Smart Citation

Effect of albumin infusion on oxidative albumin modification and albumin binding capacity in chronic liver failure

Stauber,

Paar,

Balazs

et al. 2023

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Oxidative albumin modification and impaired albumin binding function have been described both in chronic liver failure and for therapeutic albumin solutions. The aim of the present study was to evaluate the effect of albumin infusion on redox state and binding function of circulating albumin. We studied 20 patients with cirrhosis who routinely received albumin infusions for prevention of post‐paracentesis circulatory dysfunction or treatment of hepatorenal syndrome. We measured albumin fractions by redox state of cysteine‐34 and albumin binding properties using dansylsarcosine as site II ligand. Therapeutic albumin solutions showed high contents of human nonmercaptalbumin‐1 and human nonmercaptalbumin‐2, exceeding the respective values in our patients with decompensated cirrhosis. An initial protocol for the first nine patients sampled at baseline, 24 h and 48 h after albumin infusion revealed no significant changes of oxidized albumin species or albumin binding properties. However, a modified protocol for the remaining 11 patients sampled at baseline, <1 h after and 24 h after albumin infusion revealed short‐lived changes of oxidized albumin species while no changes in albumin binding properties were observed. In conclusion, therapeutic albumin infusion transiently changed albumin redox state but did not improve binding function of circulating albumin in chronic liver failure.

show abstract

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 87%

Effect of albumin infusion on oxidative albumin modification and albumin binding capacity in chronic liver failure

Stauber,

Paar,

Balazs

et al. 2023

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…The study showed that plasmapheresis induced a severe and long-lasting change in endogenous irreversibly oxidized albumin levels during the course of treatment and 12 days after the last plasmapheresis, which was not the case in patients treated with IA [176]. Nevertheless, they found a mean decrease in albumin concentration of about 4.7 g/l during one IA treatment with the proportion of increased irreversibly oxidized albumin over five IA treatments within the normal range [176]. It should be noted that IA is an apheresis technique where commercial albumin is not administered as a replacement fluid (just as is the case with our nanomembrane-based TPE).…”

Section: The Role Of Tpe As An Os Modulatormentioning

confidence: 84%

“…However, there are controversial data on cohorts without hypoalbuminemia in MS patients as well [174,175]. So far, there is only one study that longitudinally analyzed the effect of plasmapheresis or immunoabsorption (IA) on albumin quantity and redox state in patients with autoimmune-mediated neurological disorders [176]. The study showed that plasmapheresis induced a severe and long-lasting change in endogenous irreversibly oxidized albumin levels during the course of treatment and 12 days after the last plasmapheresis, which was not the case in patients treated with IA [176].…”

Section: The Role Of Tpe As An Os Modulatormentioning

confidence: 99%

“…So far, there is only one study that longitudinally analyzed the effect of plasmapheresis or immunoabsorption (IA) on albumin quantity and redox state in patients with autoimmune-mediated neurological disorders [176]. The study showed that plasmapheresis induced a severe and long-lasting change in endogenous irreversibly oxidized albumin levels during the course of treatment and 12 days after the last plasmapheresis, which was not the case in patients treated with IA [176]. Nevertheless, they found a mean decrease in albumin concentration of about 4.7 g/l during one IA treatment with the proportion of increased irreversibly oxidized albumin over five IA treatments within the normal range [176].…”

Section: The Role Of Tpe As An Os Modulatormentioning

confidence: 99%

See 1 more Smart Citation

Oxidative Stress and the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Pathway in Multiple Sclerosis: Focus on Certain Exogenous and Endogenous Nrf2 Activators and Therapeutic Plasma Exchange Modulation

Tonev,

Momchilova

2023

IJMS

View full text Add to dashboard Cite

The pathogenesis of multiple sclerosis (MS) suggests that, in genetically susceptible subjects, T lymphocytes undergo activation in the peripheral compartment, pass through the BBB, and cause damage in the CNS. They produce pro-inflammatory cytokines; induce cytotoxic activities in microglia and astrocytes with the accumulation of reactive oxygen species, reactive nitrogen species, and other highly reactive radicals; activate B cells and macrophages and stimulate the complement system. Inflammation and neurodegeneration are involved from the very beginning of the disease. They can both be affected by oxidative stress (OS) with different emphases depending on the time course of MS. Thus, OS initiates and supports inflammatory processes in the active phase, while in the chronic phase it supports neurodegenerative processes. A still unresolved issue in overcoming OS-induced lesions in MS is the insufficient endogenous activation of the Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) pathway, which under normal conditions plays an essential role in mitochondria protection, OS, neuroinflammation, and degeneration. Thus, the search for approaches aiming to elevate endogenous Nrf2 activation is capable of protecting the brain against oxidative damage. However, exogenous Nrf2 activators themselves are not without drawbacks, necessitating the search for new non-pharmacological therapeutic approaches to modulate OS. The purpose of the present review is to provide some relevant preclinical and clinical examples, focusing on certain exogenous and endogenous Nrf2 activators and the modulation of therapeutic plasma exchange (TPE). The increased plasma levels of nerve growth factor (NGF) in response to TPE treatment of MS patients suggest their antioxidant potential for endogenous Nrf2 enhancement via NGF/TrkA/PI3K/Akt and NGF/p75NTR/ceramide-PKCζ/CK2 signaling pathways.

show abstract